Építés alatt – nem éles oldal
Belépés

What researchers published on Zsírmáj (MASLD/MASH)

40 075 papers, newest first.

Showing 180 of 40 075

  • All-cause mortality across cryptogenic steatotic liver disease and MASLD phenotypes: an NHANES III cohort study.Endocrine
  • ÁttekintésBiomarkers to assess early signs of fibro-inflammatory disease modification following short-term therapeutic intervention in people living with MASLD/MASH: A systematic scoping review.PloS one
  • ÁttekintésStage-predominant epigenetic framework across the MASLD spectrum: global evidence and the Saudi Arabian context.Epigenomics
  • How low can you go? Is lower-dose vitamin E effective and safe for MASH?Hepatology (Baltimore, Md.)
  • Mediation Analysis of Inflammatory Biomarkers in the Association Between Metabolic Dysfunction-Associated Steatotic Liver Disease and Sarcopenia Among US Adults With Type 2 Diabetes or Prediabetes.International journal of endocrinology
  • Finding the hidden epidemic: screening for metabolic dysfunction-associated steatotic liver disease.Proceedings (Baylor University. Medical Center)
  • Two drugs, one liver: A real-world test of GLP-1 RA and SGLT-2i combination therapy in MASLD.Hepatology (Baltimore, Md.)
  • ÁttekintésHepatic metabolic plasticity: From physiological adaptation to energy overload-associated pathological progression and therapeutic targeting.Journal of physiology and biochemistry
  • Integrative transcriptomic and single-nucleus analyses identify microbiota-metabolite-associated immune signatures of fibrosis severity in MASLD.PloS one
  • Proteome-Wide Genetic Study Identified ENTPD5 as a Candidate Target for Obesity-Related MASLD.Obesity (Silver Spring, Md.)
  • Cold-Shock-Primed Lactobacillus rhamnosus GG Extracellular Vesicles Restore Liver-Gut Axis Homeostasis Through Bile Acid Metabolic Reprogramming in MASLD.Journal of extracellular vesicles
  • Analysis of drug development risks for metabolic dysfunction-associated steatotic liver disease from a sustainable accounting perspective.Cost effectiveness and resource allocation : C/E
  • The prevalence of metabolic syndrome in patients with non-alcoholic fatty liver disease: Systematic review and meta-analysis of observational studies.Sage open chronic disease
  • ÁttekintésUltrasound quantification of liver fat in MASLD.European radiology
  • Human placenta extract declines fat deposition in an in vitro novel 3D MASLD model.In vitro models
  • Carbon Dots Derived from Carbonized Citri Reticulatae Pericarpium (Chenpi) Alleviate Metabolic Dysfunction-Associated Steatohepatitis.Molecules (Basel, Switzerland)
  • Reply to Khan and Shoro: Endoscopic ultrasound strain elastography in metabolic dysfunction-associated steatotic liver disease: Evaluation against transient elastography and non-invasive markers.Hepatology forum
  • Randomizált vizsgálatEffects of Whole "Navelina" Orange Consumption on Glucose Homeostasis and Fructosamine Levels in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Randomized Controlled Trial.Nutrients
  • ÁttekintésThe role and mechanisms of the vascular microenvironment in metabolic dysfunction- associated fatty liver disease.Frontiers in endocrinology
  • Early Metabolic and Cardiovascular Alterations in Adolescents with MASLD or Simple Obesity.Nutrients
  • Integrated Cardiovascular-Kidney-Metabolic Disease Burden in Mexico: Trends from 2000 to 2023 and Projections to 2050.Annals of global health
  • Growth Hormone Reduces Liver Tumor Development in a MASLD-Related HCC Murine Model.International journal of molecular sciences
  • Renal Multiparametric MRI for Early Detection and Longitudinal Monitoring of Metabolic Dysfunction Associated Steatotic Liver Disease Associated Kidney Injury: Histopathologic Validation and Multi-Omics Profiling.Journal of magnetic resonance imaging : JMRI
  • Clinical Advances in Metabolic Dysfunction-Associated Steatotic Liver Disease: Context, Measurement, and Treatment.Journal of clinical medicine
  • ÁttekintésNavigating MASLD heterogeneity: from metabolic risk to precision stratification.Frontiers in medicine
  • Gut microbiota dysbiosis and altered short-chain fatty acid biosynthetic pathways in Chinese children with obesity and nonalcoholic fatty liver disease.Frontiers in endocrinology
  • MetaanalízisSilymarin-Based Therapies in Chronic Liver Disease: A Systematic Review of Biochemical, Cardiometabolic, Steatosis, and Fibrosis-Related Outcomes.Nutrients
  • Network toxicology, molecular docking and in vitro validation reveal the molecular mechanisms of bisphenol A-induced MASLD.Frontiers in pharmacology
  • Circadian Rhythm-Related Characteristics and Adiposity in Relation to CAP-Defined Hepatic Steatosis Among Shift and Non-Shift Workers: A Pilot Study.Nutrients
  • Short- and Medium-Chain Fatty Acid Profiles in Biopsy-Proven Metabolic Dysfunction-Associated Steatotic Liver Disease: A Cross-Sectional Study.Nutrients
  • Chronic Consumption of Ghee (Clarified Butter) and Coconut Oil, but Not Palmolein, Induces Microvesicular Steatosis, Insulin Resistance, and Inflammation in Mice Fed a High-Fat Diet.Nutrients
  • Association Between Free Triiodothyronine and Metabolic Dysfunction-Associated Steatotic Liver Disease in Euthyroid Population: Evidence from NHANES 2007-2012.Healthcare (Basel, Switzerland)
  • Transcriptomic Profiling Identifies Hub Transcription Factors Associated with the Protective Effects of Licochalcone A Against HFD-Induced MASLD.Nutrients
  • Szisztematikus áttekintésUltra-Processed Food Consumption and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Evidence Synthesis, Methodological Appraisal, and Mechanistic Insights.Nutrients
  • ÁttekintésNutritional Impairment and Muscle Health in MASLD: The Potential Role of Eating Behaviors.Journal of clinical medicine
  • Multiparametric 0.4-T low-field MRI mapping for metabolic dysfunction-associated steatotic liver disease in rats.European radiology experimental
  • Altered Hepatic Hydrogen Sulfide-Related Homeostasis in Metabolic Dysfunction-Associated Steatotic Liver Disease and Its Changes Following Sleeve Gastrectomy.Journal of clinical medicine
  • ÁttekintésStatins and the Lifetime Outcomes of MASLD: From Evidence Asymmetry to Outcome Convergence.International journal of molecular sciences
  • Bacillus megaterium 1259 Limits Hepatic Lipid Accumulation in Mice with Established Diet-Induced Obesity: Paired Hepatic Transcriptomic and Metabolomic Profiling.Nutrients
  • MetaanalízisLarge-Scale Transcriptomic Meta-Analysis of Mouse Liver Responses to High-Fat Diet Identifies a Reproducible Core and Duration-Associated Variation.International journal of molecular sciences
  • ÁttekintésTrained Immunity and Persistent Myeloid Responsiveness in MASH.Cells
  • ÁttekintésMitochondrial Fatty Acid Oxidation Dysregulation in Metabolic Dysfunction-Associated Steatotic Liver Disease: Mechanistic Roles and Emerging Diagnostic and Therapeutic Advances.Pharmacological research
  • MRI-Derived Muscle Composition and Visceral Adiposity in Relation to Mortality and Vascular Outcomes in MASLD.Diagnostics (Basel, Switzerland)
  • Response to "Endoscopic ultrasound strain elastography in metabolic dysfunction-associated steatotic liver disease: Evaluation against transient elastography and non-invasive markers".Hepatology forum
  • Integrated chemical profiling and lipidomics reveal that Mailuoning oral liquid alleviates diet-induced MASLD via PPARα-mediated lipid homeostasis and COX-2 inhibition, with identification of potential active constituents.Frontiers in pharmacology
  • Low-intensity pulsed ultrasound ameliorates diet-induced MASLD with hepatic lipid metabolic remodeling.Biochimica et biophysica acta. Molecular basis of disease
  • Early Sugar Exposure and the Lifelong Prevention of MASLD.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • Association between systemic immune-inflammation index and skeletal muscle mass in patients with nonalcoholic fatty liver disease: A cross-sectional study.Medicine
  • Tubastatin A Mitigates Lipotoxicity, Inflammation and Fibrosis Through Downregulation of HDAC6 and Modulation of AMPK-FGF21 Axis in Metabolic Dysfunction-Associated Steatohepatitis.Inflammation
  • Metabolic Dysfunction-Associated Steatotic Liver Disease, With and Without Increased Alcohol Intake, and Incident Atrial Fibrillation in Older Korean Adults: A Competing-Risk Cohort Study.Geriatrics & gerontology international
  • Associations of metabolic dysfunction-associated steatotic liver disease and cardiometabolic burden with urinary tubular biomarker abnormalities: a cross-sectional health examination study.Frontiers in medicine
  • Direct Remnant Lipoprotein Profiling Reveals Subfraction-Level Associations with Biopsy-Proven MASH in Severe Obesity.Journal of lipid research
  • Elevated malonic acid and 15d-PGJ2 in MASLD rats with diabetes triggered pathological cardiac remodeling through impairment of mitochondrial health and cellular metabolism.Journal of molecular and cellular cardiology
  • Targeting FSP1 to Suppress PI3K/AKT Signaling: Enarodustat Ameliorates MASH via Ferroptosis Inhibition and Lipid Metabolism Regulation.European journal of pharmacology
  • Szisztematikus áttekintésKetogenic Diet Effects on Liver Health in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Systematic Review.Liver international : official journal of the International Association for the Study of the Liver
  • ÁttekintésNutraceuticals for the prevention of liver fibrosis in metabolic dysfunction-associated steatotic liver disease (MASLD).Food science and biotechnology
  • ÁttekintésNatural Bioactive Compounds Targeting Lipid Metabolism in Metabolic Dysfunction-Associated Steatotic Liver Disease.Phytotherapy research : PTR
  • Reply to Comments to Diagnostic Value and Influencing Factors of Ultrasound-Derived Fat Fraction for Quantifying MASLD in Children.Liver international : official journal of the International Association for the Study of the Liver
  • ÁttekintésCompositional diversity and dietary implications of cereal and legume crops as functional resources for non-alcoholic fatty liver disease prevention: a review.Food science and biotechnology
  • Association of longitudinal serum 25-hydroxyvitamin D trajectories with subsequent liver stiffness increase in patients with early-onset type 2 diabetes and metabolic dysfunction-associated steatotic liver disease.Frontiers in endocrinology
  • Total-Body 18F-FAPI PET/CT for Assessment of Metabolic Dysfunction-Associated Steatotic Liver Disease: A Pilot Study.Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • ÁttekintésTherapeutic opportunities of fecal microbiota transplantation in the treatment of non-alcoholic fatty liver disease.Frontiers in cellular and infection microbiology
  • ATM safeguards liver homeostasis by mitigating mitochondrial hypermetabolism and bioenergetic crisis in MASLD.EMBO molecular medicine
  • Áttekintés[Research progress on male reproductive function impairment caused by metabolic dysfunction-associated steatotic liver disease].Zhonghua nan ke xue = National journal of andrology
  • Correction: Prevalence and steatosis severity of MASLD in patients with type 2 diabetes mellitus in Kuwait.Frontiers in endocrinology
  • Investigating the regulatory potential of interval training and IPA supplementation on modulating the hepatic gluconeogenesis pathway in rats with non-alcoholic fatty liver disease.BMC gastroenterology
  • Cognitive impairment in metabolic dysfunction-associated steatotic liver disease ‒ Clinical evidence, liver-brain mechanisms and research priorities.Revista espanola de enfermedades digestivas
  • ÁttekintésFructose-related metabolic stress in MASLD: integrating intestinal substrate partitioning, hepatic phosphorus metabolite dynamics, and the inflammatory-fibrotic interface.Frontiers in medicine
  • A Minimally Invasive Diagnostic Platform Compatible with Tissue and Serum Analysis for Early Detection of Non-Alcoholic Fatty Liver Disease.Analytical chemistry
  • Joint effects of phenotypic age acceleration and novel insulin resistance indicators on mortality in adults with metabolic dysfunction-associated steatotic liver disease: a prospective cohort study.Cardiovascular diabetology
  • Metabolic dysfunction-associated steatotic liver disease: Delphi consensus with specialists on comprehensive approach, public health policies, and primary care physicians' perspectives.Gaceta medica de Mexico
  • Machine learning-based prediction of non-alcoholic fatty liver disease in Chinese perimenopausal women: a retrospective observational study.BMJ open
  • Changing etiological spectrum and the rise of metabolic risk in liver cancer burden in China (1990-2021) with projections to 2036: a decomposition analysis based on the GBD 2021 study.BMC cancer
  • An Enzyme-Triggered Self-Immobilizing Dual-Modal Probe for Precision Imaging and Sustained Gas Therapy of Early-Stage MASH.Analytical chemistry
  • ÁttekintésPredicting response to GLP-1-based therapy in MASLD/MASH: an evidence-tiered, endpoint-specific framework built on host genotype and gut microbial features.Frontiers in endocrinology
  • Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 48-week results from a multicentre, randomised, double-blind, phase 2b study.The lancet. Gastroenterology & hepatology
  • Associations of cumulative exposure and dynamic trajectories of the normalized creatinine-to-cystatin C ratio with incident cardiovascular disease in middle-aged and older Chinese adults with metabolic dysfunction-associated steatotic liver disease: a nationwide cohort study.BMC cardiovascular disorders
  • Biological sex modifies the link between nutrient intake and metabolic dysfunction-associated steatotic liver disease: intrinsic oxidative vulnerability in females.Journal of the Endocrine Society
  • GLP-1-based Therapies in MASH: From Metabolic Benefits to an Improvement in Liver Fibrosis.Internal medicine (Tokyo, Japan)
  • Szisztematikus áttekintésPolyamine Dysregulation in Metabolic Dysfunction-associated Steatotic Liver Disease: a Systematic Review of Human Observational Evidence.Current obesity reports
  • Claims-defined hepatic steatosis compatible with MASLD and reproductive outcomes after the first observed embryo transfer: a Korean nationwide cohort study.BMC gastroenterology
  • Decoding Mitochondrial CircRNA Dynamics with In Situ Super-Resolution Bioimaging and Quantification via a Ratiometric DNA Tetrahedral Amplifier.Analytical chemistry
  • Elevated Risk of Bladder Cancer Associated With Metabolic Dysfunction-Associated Steatotic Liver Disease in Elderly Korean Men: A Nationwide Cohort Study.Journal of Korean medical science
  • ÁttekintésHepatocyte-derived lipid droplets in MASH: macrophage sensing and inflammation.Frontiers in immunology
  • Conventional Preoperative Prediction of MASLD-Compatible Histologic Abnormality, Fibrosis, and Higher-Grade Steatohepatitis, and Exploratory Machine-Learning Classification of MASH Severity in Patients Undergoing Roux-en-Y Gastric Bypass.Obesity surgery
  • Longitudinal Changes in Physical Performance with Metabolic Dysfunction-Associated Steatotic Liver Disease and Coronary Artery Disease.Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association
  • Unresolved questions for nutrient-stimulated hormonal multi-agonists in MASH; more receptors, better livers?: Editorial on "Engineered nutrient-stimulated hormonal multi-agonists for precision targeting of obesity and metabolic disorders".Clinical and molecular hepatology
  • ÁttekintésDietary interventions in metabolic dysfunction-associated steatotic liver disease: current evidence, research priorities, and clinical translation.Clinical and experimental hepatology
  • Liquiritigenin Ameliorates Metabolic Dysfunction-Associated Steatotic Liver Disease via AMPK-Mediated Dual Activation of PPARα/PPARγ.Food science & nutrition
  • Elevated circulating activin A is associated with disease severity in advanced steatotic liver disease (SLD).BMC gastroenterology
  • Neuro-immune and metabolic disorders in association with depression, anxiety, and chronic fatigue-fibromyalgia symptoms due to nonalcoholic fatty liver disease.CNS spectrums
  • EsetismertetésGlycogenic Hepatopathy Mimicking Overlapping with Metabolic Dysfunction-Associated Steatotic Liver Disease in Newly Diagnosed Type 2 Diabetes: A Case Report.SAGE open medical case reports
  • Comment on "Effect of High Dose N-Acetyl Cysteine Supplementation on Markers of Oxidative Stress and Insulin Resistance in Non-Diabetic Patients With Metabolic Dysfunction Associated Steatotic Liver Disease: A Randomized Controlled Trial".Journal of gastroenterology and hepatology
  • 3β-trans-CLD alleviates metabolic dysfunction-associated steatotic liver disease (MASLD) via modulating the IDO1/Nrf2/SREBP1/SCD1 axis in vitro.Fitoterapia
  • ÁttekintésEffects of Bacterial-Derived Extracellular Vesicles in Rodent Models of Obesity, Metabolic Dysfunction-Associated Steatotic Liver Disease and Insulin Resistance/type 2 Diabetes. A Systematic Review.Probiotics and antimicrobial proteins
  • Propolis Supplementation in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Phytotherapy research : PTR
  • DTC1225, a novel benzothiazole-based compound, ameliorates MASLD by restoring metabolic-redox homeostasis and promoting hepatic lipid remodeling.Metabolism: clinical and experimental
  • Numerical reproducibility and threshold interpretation in MASLD risk stratification.Clinical and molecular hepatology
  • Letter to the Editor on "Normal-weight MASLD: reclassification, characteristics, and adverse liver outcomes across diverse populations".Clinical and molecular hepatology
  • Efinopegdutide: a step towards precision in MASH therapy?Lancet (London, England)
  • What Does Normal BMI Hide in MASLD? Body Composition and Cause-Specific Mortality After Reclassification: Authors' reply.Clinical and molecular hepatology
  • GLP-1/Glucagon Receptor Dual Agonists for Metabolic Dysfunction-Associated Steatohepatitis and Steatotic Liver Disease (MASH/MASLD): A Systematic Review and Meta-Analysis.Digestive diseases (Basel, Switzerland)
  • TMEM189/PEDS1 deficiency aggravates MASH progression by promoting FASN-mediated macrophage activation.Cell death & disease
  • Clarifying local price mapping, response thresholds, and re-treatment structure in MASLD cost-effectiveness modeling.Clinical and molecular hepatology
  • Saroglitazar Facilitates Insulin De-escalation and Improves Metabolic Parameters in Pioglitazone-Ineligible Non-metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Type 2 Diabetes: Real-World Evidence From India.Cureus
  • Quantitative fragility of reported association between aspirin use and hepatocellular carcinoma risk in metabolic dysfunction-associated steatotic liver disease: Letter to the editor on "Aspirin and hepatocellular carcinoma risk in metabolic dysfunction-associated steatotic liver disease: Nationwide cohort study with genetic risk analysis".Clinical and molecular hepatology
  • A Liver-Targeted CIDEB siRNA in Adults with MASLD.The New England journal of medicine
  • Reply: Thoughts on the clinical translation of dynamic fibrosis risk assessment models in MASLD.Clinical and molecular hepatology
  • Efficacy and safety of efinopegdutide in adults with metabolic dysfunction-associated steatohepatitis and stage 2-3 fibrosis: a phase 2b, randomised, placebo-controlled study.Lancet (London, England)
  • Sex-Specific Risk Thresholds of Binge-Drinking Frequency for Advanced Fibrosis in MetALD and ALD: Analysis of the NHANES Cohort.Alcohol, clinical & experimental research
  • Correspondence on reply to "Quantitative fragility of reported association between aspirin use and hepatocellular carcinoma risk in MASLD".Clinical and molecular hepatology
  • Beyond BMI in MASLD: Rethinking Lean Phenotypes and Metabolic Risk Stratification: Authors' reply.Clinical and molecular hepatology
  • Reply to "Quantitative fragility of reported association between aspirin use and hepatocellular carcinoma risk in MASLD".Clinical and molecular hepatology
  • Beyond BMI in MASLD: Rethinking Lean Phenotypes and Metabolic Risk Stratification: Letter to the Editor on "Normal-weight metabolic dysfunction-associated steatotic liver disease: reclassification, characteristics, and adverse liver outcomes across diverse populations".Clinical and molecular hepatology
  • Reply to correspondence on "Outcomes of oral antidiabetic drugs in metabolic dysfunction-associated steatotic liver disease: a nationwide target trial emulation study".Clinical and molecular hepatology
  • Correspondence on an Editorial regarding "DNMT1 Conducts the Epigenetic Symphony Shaping MASLD Progression".Clinical and molecular hepatology
  • Health-care burden of metabolic dysfunction-associated steatotic liver disease in European tertiary-care outpatient clinics (CONSTANS): a prospective multicentre cohort study.The Lancet regional health. Europe
  • Author Reply to Letter to the Editor Regarding ''Beyond Awareness: A Qualitative Assessment of Barriers and Facilitators to Implementing Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD) Care Pathways in Primary Care''.Gastro hep advances
  • PreprintHepatocyte UBE4A protects against MASLD and MASH by maintaining ER homeostasis via UBXN4 interaction.bioRxiv : the preprint server for biology
  • Mapping the NASH-CHECK to the EQ-5D-5L in a MASLD population in seven European countries.Health and quality of life outcomes
  • Revisiting alpha-fetoprotein thresholds for hepatocellular carcinoma surveillance in the metabolic dysfunction-associated steatotic liver disease era: time for an evidence-based recalibration.Journal of gastrointestinal oncology
  • Native T1 mapping radiomics for assessing FIB-4-associated fibrosis risk in metabolic dysfunction-associated steatotic liver disease.Quantitative imaging in medicine and surgery
  • Superiority of magnetic resonance elastography and proton density fat fraction: an umbrella meta-analysis of non-invasive imaging for hepatic steatosis and fibrosis in metabolic dysfunction-associated steatotic liver disease and chronic hepatitis B.Quantitative imaging in medicine and surgery
  • ÁttekintésWill GLP-1-based therapies reshape the epidemiology of MASLD? An emerging public health perspective.Frontiers in endocrinology
  • Identification of Neuroinflammation-Related Diagnostic Biomarkers in Metabolic Dysfunction-Associated Steatohepatitis: An Integrated Bioinformatics and Machine Learning Approach.Gastroenterology research and practice
  • Corrigendum to "Total extract of Folium Rhododendri Daurici alleviate MASLD by regulating PPAR and TNF signaling pathways" [J. Ethnopharmacol. 358, (2026), 120955].Journal of ethnopharmacology
  • Exposure to emerging and legacy PFAS and risks of metabolic dysfunction-associated steatotic liver disease and liver fibrosis in adults living near a semiconductor science park.Journal of hazardous materials
  • Metabolic syndrome and liver fibrosis in nondiabetic MASLD: A cross-sectional double machine learning study.Medicine
  • ÁttekintésAdipose tissue dysfunction and the liver: reframing MASH as the hepatic expression of systemic metabolic dysfunction.Frontiers in endocrinology
  • ÁttekintésMetabolic Dysfunction-Associated Steatotic Liver Disease and Sudden Cardiac Death: Epidemiology, Mechanisms, Risk Stratification, and Prevention.Heart rhythm
  • ÁttekintésFrom periodontal inflammation to hepatic immune remodeling: emerging concepts of myeloid reprogramming in stage-dependent MASLD.Frontiers in immunology
  • Mevalonate pathway regulates double-negative regulatory T cell stability in metabolic dysfunction-associated steatotic liver disease.Science advances
  • Thyroid-stimulating hormone-body mass index profile and mortality in metabolic dysfunction-associated steatotic liver disease.iLIVER
  • Lean metabolic dysfunction-associated steatotic liver disease.Current opinion in endocrinology, diabetes, and obesity
  • Developing and Externally Validating Explainable Machine Learning for Elastography-Defined Steatotic Liver Disease.Journal of visualized experiments : JoVE
  • SGLT2 inhibitor and fibrosis progression in MASLD: Correspondence to letter to the editor on "Comparative risk of fibrosis progression with sodium-glucose cotransporter-2 vs. dipeptidyl peptidase-4 inhibitors in metabolic dysfunction-associated steatotic liver disease and type 2 diabetes mellitus with low-to-intermediate fibrosis".Clinical and molecular hepatology
  • Megfigyeléses vizsgálatFasting glucose-to-HDL cholesterol ratio and risk of MASLD in nonobese Chinese adults: A retrospective cohort study.Medicine
  • Association of Vascular Endothelial Growth Factor A +936 C/T Polymorphism With Non-Alcoholic Fatty Liver Disease in a Bangladeshi Population: A Case-Control Study.Health science reports
  • Trichrome-based deep learning for quantitative assessment of steatosis, hepatocellular ballooning, and fibrosis in metabolic dysfunction-associated steatohepatitis.Virchows Archiv : an international journal of pathology
  • Association of Triglyceride-to-HDL Cholesterol ratio with Body Mass Index in Nepalese Adults with Non-Alcoholic Fatty Liver Disease.Kathmandu University medical journal (KUMJ)
  • ÁttekintésThe Integrative Mechanism of Xiaoyaosan Through Liver-Brain Crosstalk in the Treatment of Depression Combined with MASLD.Drug design, development and therapy
  • Sex differences in the prevalence of metabolic dysfunction-associated steatotic liver disease in hospitalized patients: a single-center cross-sectional study.Frontiers in endocrinology
  • Correspondence to letter to the editor on "Evaluating treatment response thresholds for cost-effective treatment in metabolic dysfunction-associated steatotic liver disease".Clinical and molecular hepatology
  • Gudan Wan attenuates metabolic dysfunction-associated steatohepatitis by modulating autophagy and the Bcl-2/Caspase-3/Caspase-8 apoptotic axis.Frontiers in cell and developmental biology
  • Frequency and significance of rare LIPA variants associated with lysosomal acid lipase deficiency in metabolic dysfunction-associated steatotic liver disease: Results from the Nonalcoholic Steatohepatitis Clinical Research Network.Journal of pediatric gastroenterology and nutrition
  • Engineered Chiral Probiotics Ameliorate MASH via Gut-Liver Axis.Advanced science (Weinheim, Baden-Wurttemberg, Germany)
  • Relationship between triglyceride-high-density lipoprotein cholesterol-glucose-body index and nonalcoholic fatty liver disease in Chinese middle-aged and older adults: a secondary analysis of a cross-sectional cohort.BMC endocrine disorders
  • ÁttekintésMetabolic dysfunction-associated steatotic liver disease: Pathogenesis, complications and pharmacological treatment.EXCLI journal
  • Construction of a NAFLD identification model in Xizang population and exploration of risk factors related to liver fibrosis.BMC gastroenterology
  • MASLD clusters in multi-ethnic populations: similar subtypes with varying fibrosis outcomes.BMC gastroenterology
  • Lean MAFLD as an independent risk factor for carotid plaque: The value of FIB-4 index in subgroup analysis.PloS one
  • Annualized fibrosis dynamics in metabolic dysfunction-associated steatotic liver disease: a paired-biopsy cohort.Journal of gastroenterology
  • TUDCA was identified as a potential therapeutic drug for nonalcoholic steatohepatitis complicated with hypercholesterolemia targeting ADRA2C by integrated bioinformatics and experimental verification.Biology direct
  • Association between the red blood cell distribution width to albumin ratio and cardiovascular outcomes in MASLD patients: a national cohort study integrating machine learning.BMC cardiovascular disorders
  • ÁttekintésNoninvasive Diagnosis of Hepatocellular Carcinoma Outside Guideline-Defined High-Risk Populations: Evolving Perspectives in the Era of MASLD.Korean journal of radiology
  • Patient Awareness and Disease Burden in MASLD: A Large-Scale Survey.JHEP reports : innovation in hepatology
  • Comparing attenuation parameter and liver stiffness measurement using Hepatus and Fibroscan for the evaluation of steatosis and fibrosis in patients with chronic liver disease: A prospective study.PloS one
  • ÁttekintésSelenium Nanoparticles in Atherosclerosis and Non-Alcoholic Fatty Liver Disease: A Comprehensive Review of Therapeutic Mechanisms, Targeted Delivery, and Translational Prospects.International journal of nanomedicine
  • IL-34 ameliorates MASLD by regulating the synthesis of gut microbiota-derived metabolites LPS and IMP.Cellular and molecular life sciences : CMLS
  • Sodium Butyrate Ameliorates Hepatic Steatosis and Insulin Resistance in MASLD Models With Concurrent Alterations in AMPK and PI3K/AKT Signaling.Frontiers in bioscience (Landmark edition)
  • UHPLC-Q-TOF-MS Identification of Intestinal Absorbable Components of Yindan Pinggan Capsule and Exploration of Its Anti-NAFLD Mechanism Based on NF-κB Signaling Regulation.Biomedical chromatography : BMC
  • GAN diet-induced MASLD is associated with compartment-dependent transcriptional alterations in orthotopic hepatocellular carcinoma and adjacent liver.Biochemical and biophysical research communications
  • Jujuboside A ameliorates T2DM-associated MASH: Suppression of YY1/FAS axis-mediated hepatic de novo fatty acid biosynthesis.The Journal of nutritional biochemistry
  • Boldine ameliorates metabolic dysfunction-associated steatotic liver disease via Nrf2-mediated mitochondrial and ferroptotic regulation.Archives of biochemistry and biophysics
  • Upregulation of serum expression of miR-217 in non alcoholic fatty liver disease.Molecular biology research communications
  • Circulating Estradiol as an Independent Risk Factor for Metabolic Dysfunction-Associated Steatotic Liver Disease and Fibrosis Risk in Women: Evidence From a Multicenter Health-Checkup Cohort.Journal of Korean medical science
  • ÁttekintésMetabolic Dysfunction-Associated Steatotic Liver Disease and Extrahepatic Cancers.British journal of hospital medicine (London, England : 2005)
  • Estimated glucose disposal rate outperforms other insulin resistance surrogate indices in predicting cardiometabolic disease and major adverse cardiovascular events in metabolic dysfunction-associated steatotic liver disease: insights from UK Biobank.Cardiovascular diabetology
  • ÁttekintésGut microbiota and treatment response heterogeneity across pharmacological therapies for MASH.Frontiers in pharmacology
  • ÁttekintésMolecular smugglers in obesity-driven MASLD: Snitching on adipose-derived extracellular vesicles.Acta pharmaceutica Sinica. B
  • Letter: Interpreting Rule-Out and Rule-In Enhanced Liver Fibrosis Thresholds in Metabolic Dysfunction-Associated Steatotic Liver Disease. Authors' Reply.Alimentary pharmacology & therapeutics
  • Serum Interferon Gamma-induced Protein 10 Levels in Patients with Type 2 Diabetes and Metabolic Dysfunction-associated Steatotic Liver Disease: A Case-control Study.Saudi journal of medicine & medical sciences
  • A bioactive ginsenoside alleviates hepatocellular ferroptosis induced by oxidized phospholipid accumulation in nonalcoholic steatohepatitis.iMeta
  • GLP-1 Receptor Agonists in Metabolic Dysfunction-Associated Steatotic Liver Disease and Cardiovascular Disease: A Review.Cardiology in review
  • Duodenal-Jejunal Bypass Stent Versus Laparoscopic Sleeve Gastrectomy in Patients With Obesity and MASLD: Short-Term Efficacy and Perioperative Safety in a Retrospective Cohort Study.Diabetes, obesity & metabolism
  • Early Changes in Peripancreatic Mesenteric Fat Beyond Weight Loss Predict Durability of Hepatic Improvements in MASLD.Diabetes, obesity & metabolism
  • Atractylenolide III alleviates MASLD by inhibiting lipid synthesis and apoptosis via PTEN.Phytomedicine : international journal of phytotherapy and phytopharmacology
  • Sleep Efficiency and Physical Capacity in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Cross-Sectional Study.Journal of sleep research
  • High Discrimination, Uncertain Triage: Interpreting Ultrasound-Based MASH Risk Classification.Journal of gastroenterology and hepatology
  • Therapeutic Signals Without Histologic Certainty: FGF Analogues in Compensated MASH Cirrhosis-A Systematic Review and Meta-Analysis.Diabetes, obesity & metabolism